Benzinga | Jun 4, 2021 09:15AM EDT

Deciphera Pharmaceuticals Presents Data from QINLOCK and Rebastinib Programs at the 2021 American Society of Clinical Oncology Annual Meeting

-- Exploratory Analysis of the INVICTUS Phase 3 Study Showed QINLOCK Dose Escalation After Disease Progression Provided Substantial Clinical Benefit in Advanced GIST --

-- Rebastinib in Combination with Paclitaxel in a Phase 1b/2 Study Demonstrated Median Progression Free Survival of 6.2 Months in Heavily Pretreated Patients with Endometrial Cancer --